You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 16, 2025

Details for Patent: 10,011,633


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,011,633 protect, and when does it expire?

Patent 10,011,633 protects BYLVAY and is included in one NDA.

This patent has sixty-eight patent family members in thirty-two countries.

Summary for Patent: 10,011,633
Title:IBAT inhibitors for the treatment of liver diseases
Abstract: The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
Inventor(s): Gillberg; Per-Goran (Molndal, SE), Graffner; Hans (Helsingborg, SE), Starke; Ingemar (Gothenburg, SE)
Assignee: Albireo AB (Gothenburg, SE)
Application Number:15/726,071
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 10,011,633: A Comprehensive Analysis

Introduction

Patent 10,011,633, like any other patent, is a complex document that outlines the scope and claims of an invention. To fully understand its implications, it is crucial to delve into the patent's specifics, the broader patent landscape, and recent updates in patent law.

Patent 10,011,633 Overview

Patent Title and Abstract

While the specific details of Patent 10,011,633 are not provided in the sources, a typical analysis would start with the patent title and abstract. These sections give a brief overview of the invention, including its purpose, key features, and the problems it solves.

Claims

The claims section is the heart of any patent, as it defines the scope of the invention. Claims can be independent or dependent and must be clear, concise, and fully supported by the description in the patent specification[3].

Types of Claims

Independent Claims

Independent claims stand alone and define the invention without reference to other claims. They are crucial because they set the broadest scope of the invention[3].

Dependent Claims

Dependent claims refer back to an independent claim and further limit the scope of the invention. They often add specific details or features to the independent claim.

Subject Matter Eligibility

Recent USPTO Guidance

The 2024 USPTO guidance update on AI patent eligibility is particularly relevant when analyzing the subject matter eligibility of any patent, including 10,011,633. This update emphasizes the importance of integrating judicial exceptions into practical applications. For a claim to be patent-eligible, it must impose meaningful limits on the exception, transforming the abstract idea into a concrete technological improvement[1].

Practical Applications

Highlighting real-world applications of the claimed method or system is vital. Demonstrating how the abstract idea is applied in a way that provides concrete benefits or solves specific problems in the relevant field is crucial for patent eligibility. For example, if a claim involves routine data processing without any practical application, it may be considered ineligible. However, if the claim specifies the use of the data in a real-time system to enhance functionality, it could be deemed patent-eligible[1].

Patent Scope and Breadth

Metrics for Measuring Patent Scope

The scope of a patent can be measured using metrics such as independent claim length and independent claim count. These metrics have explanatory power for several correlates of patent scope, including patent maintenance payments, forward citations, and the breadth of patent classes. Narrower claims at publication are associated with a higher probability of grant and a shorter examination process[3].

Impact on Innovation

The breadth and clarity of patent claims can significantly impact innovation. Overly broad patents can diminish incentives for innovation due to increased licensing and litigation costs. Therefore, it is essential to ensure that the claims of Patent 10,011,633 are well-defined and not overly broad.

Patent Landscape and Recent Developments

False Patent Claims and Lanham Act Violations

Businesses must be cautious when making claims about the patented status of their products to avoid Lanham Act violations. Falsely claiming a product or feature is patented can lead to claims of false advertising, as seen in the Federal Circuit ruling in Crocs, Inc. v. Effervescent, Inc. This emphasizes the importance of accuracy in patent claims and marketing materials[2].

Global Dossier and Public Search Facilities

The USPTO's Global Dossier and Public Search Facility provide valuable tools for researching and analyzing patents. These resources allow users to access file histories, classification data, and citation data for related applications, which can be crucial in understanding the patent landscape and ensuring that Patent 10,011,633 does not infringe on existing patents[4].

Small Claims Patent Court

Feasibility and Structure

The concept of a small claims patent court has been under study by the Administrative Conference of the United States (ACUS). This potential court aims to address issues associated with patent litigation costs and complexity, particularly for small entities. Understanding the feasibility and potential structure of such a court can provide insights into future patent enforcement and defense strategies[5].

Key Takeaways

  • Subject Matter Eligibility: Ensure that the claims integrate judicial exceptions into practical applications to meet patent eligibility criteria.
  • Practical Applications: Highlight real-world applications of the claimed method or system to demonstrate concrete benefits.
  • Patent Scope: Use metrics like independent claim length and count to measure and optimize patent scope.
  • Accuracy in Claims: Avoid false patent claims to prevent Lanham Act violations.
  • Research Tools: Utilize USPTO resources like the Global Dossier and Public Search Facility to analyze and ensure the validity of patent claims.

FAQs

What is the significance of the 2024 USPTO guidance update on AI patent eligibility?

The update clarifies the process for determining the patent eligibility of AI-related inventions, emphasizing the integration of judicial exceptions into practical applications and ensuring that AI-assisted inventions are evaluated on equal footing with other technologies[1].

How can false patent claims lead to legal issues?

False patent claims can lead to claims of false advertising under the Lanham Act, as seen in the Crocs, Inc. v. Effervescent, Inc. ruling. This can result in significant legal and financial repercussions[2].

What metrics can be used to measure patent scope?

Metrics such as independent claim length and independent claim count can be used to measure patent scope. These metrics have explanatory power for several correlates of patent scope, including patent maintenance payments and forward citations[3].

What is the purpose of the Global Dossier service provided by the USPTO?

The Global Dossier service allows users to access file histories, classification data, and citation data for related applications from participating IP Offices, helping to modernize the global patent system and deliver benefits to all stakeholders[4].

Why is the concept of a small claims patent court being studied?

The concept is being studied to address issues associated with patent litigation costs and complexity, particularly for small entities, and to explore the feasibility and potential structure of such a court[5].

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. Federal Circuit Ruling: False Patent Claims Can Lead to Lanham Act Violations - Buchanan Ingersoll & Rooney PC
  3. Patent Claims and Patent Scope - SSRN
  4. Search for patents - USPTO
  5. U.S. Patent Small Claims Court - Administrative Conference of the United States (ACUS)

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,011,633

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 RX Yes No 10,011,633 ⤷  Try for Free METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) ⤷  Try for Free
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 RX Yes No 10,011,633 ⤷  Try for Free METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS) ⤷  Try for Free
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 RX Yes No 10,011,633 ⤷  Try for Free METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) ⤷  Try for Free
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 RX Yes No 10,011,633 ⤷  Try for Free METHOD OF TREATING CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS) ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,011,633

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden1051165Nov 8, 2010

International Family Members for US Patent 10,011,633

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3400944 ⤷  Try for Free PA2021012 Lithuania ⤷  Try for Free
European Patent Office 3400944 ⤷  Try for Free LUC00242 Luxembourg ⤷  Try for Free
European Patent Office 3400944 ⤷  Try for Free 301157 Netherlands ⤷  Try for Free
European Patent Office 3400944 ⤷  Try for Free CA 2022 00001 Denmark ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.